Cover Image
市場調查報告書

生物科技相關支援交易及夥伴關係:最近的創業投資、企業投資資金以及其他交易分析

Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions

出版商 Kalorama Information 商品編碼 304898
出版日期 內容資訊 英文 156 Pages
訂單完成後即時交付
價格
Back to Top
生物科技相關支援交易及夥伴關係:最近的創業投資、企業投資資金以及其他交易分析 Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions
出版日期: 2014年05月20日 內容資訊: 英文 156 Pages
簡介

企業的投資額的近8分之一為對生物科技的投資。在過去數年中對生物科技的投資大幅度增加,結果從完全收購、授權合約,及各種聯盟交易等,進行了一連串複雜的交易和貿易談判。可見到這些企業資本的流入,再加上生物科技企業大幅度的創業投資流入。

本報告提供生物科技部門的投資情況相關研究,最近、現在、未來的投資情形調查分析中,概括56個主要生物科技交易的財務性詳細內容及治療藥的可能性,創業投資的投資趨勢彙整資料。

第1章 摘要整理

  • 主要調查結果
  • 調查手法

第2章 簡介

  • 調查的宗旨
    • 投資是重要的理由
    • 播種階段之後
    • 特定價值推動因素

第3章 趨勢與預測

  • 企業創業投資刺激M&A活動
  • 預測成長的授權交易
  • 堅實的創業投資的展望
  • 受關注的治療領域
  • 新策略的必要性
    • 成功可能性的模式化
    • 群眾集資
      • 生命線

第4章 洗練的協調體制造成的成長

  • 產品價值的決策
    • 定量化可能的問題
    • 革命的價值
    • 國際的價值
  • 變化的作用與市場形勢

第5章 創業投資 VS 企業資本

  • 新的資金籌措的展望
  • 武裝化策略的創業
  • 企業資本的基本

第6章 投資資金趨勢

  • 各年度指標
  • 個體化醫療

第7章 主要交易(56家公司:交易概要、規模、契約形態、詳細內容、治療藥介紹與潛在力)

  • Ablynx NV
  • Acetylon Pharmaceuticals Inc.
  • AC Immune SA
  • Adimab
  • Aileron Therapeutics Inc.
  • Algeta ASA
  • Alios BioPharma Inc.
  • Alkermes
  • Alnylam Pharmaceuticals
  • Amylin Pharmaceuticals
  • Ardea Biosciences
  • Atara Biotherapeutics
  • Avila Therapeutics
  • Boston Biomedical
  • Cellectis
  • Clarus Ventures
  • CoStim Pharmaceuticals
  • Covagen AG
  • Dicerna Pharmaceuticals Inc.
  • Editas Medicine
  • Enanta Pharmaceuticals Inc.
  • Endocyte Inc.
  • Evotec AG
  • Forma Therapeutics
  • Galapagos NV
  • Gemin X Pharmaceuticals
  • Genmab
  • GlaxoSmithKline
  • Human Genome Sciences
  • immatics Biotechnologies GmbH
  • Inhibitex
  • Inhibrx
  • Isis Pharmaceuticals Inc.
  • Juno Therapeutics
  • Macrogenics Inc.
  • Mannkind Corp.
  • Medigene AG
  • Melinta Therapeutics
  • Merck
  • Mesoblast Ltd.
  • Micromet AG
  • Moderna Therapeutics Inc.
  • OncoMed Pharmaceuticals Inc.
  • Onyx Pharmaceuticals Inc.
  • Otonomy Inc.
  • Pharmasset
  • Plexxikon Inc.
  • Reata Pharmaceuticals
  • Royalty Pharma
  • Seattle Genetics Inc.
  • Sutro Biopharma Inc.
  • Thesan Pharmaceuticals Inc.
  • UCB Inc.
  • Voyager Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Xoma Corp.
目錄
Product Code: KLI5248409

Recent Biotech Funding, Deals and Partnerships

Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic.

This Kalorama Information report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector.

Included in the report's coverage are the following data points

  • 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential
  • Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions)
  • Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions)
  • Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
  • Number of Biotech Series A Companies by Indication Oncology,
  • Platform Discovery, Diagnostics, CNS, Autoimmune)
  • Biotech Total Deal Value, 2005-2012
  • IPO Statistics
  • Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013

Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs.

This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma.

The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts.

The following are among the companies covered in this report:

  • Abbott
  • AC Immune SA
  • Adimab
  • Aileron Therapeutics Inc.
  • Atara Biotherapeutics
  • Boston Biomedical
  • Cellectis
  • Clarus Ventures
  • CoStim Pharmaceuticals
  • Covagen AG
  • Dicerna Pharmaceuticals Inc.
  • Editas Medicine
  • Enanta Pharmaceuticals Inc.
  • Endocyte Inc.
  • Evotec
  • Forma Therapeutics
  • Galapagos NV
  • Mannkind Corp.
  • Melinta Therapeutics
  • Micromet
  • Novartis
  • OncoMed
  • Onyx Pharmaceuticals Inc.
  • Otonomy Inc.
  • Pharmasset
  • Seattle Genetics Inc.
  • Royalty Pharma
  • Roche
  • Sutro Biopharma Inc.
  • Thesan Pharmaceuticals Inc.
  • UCB Inc.
  • Voyager Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Xoma Corp.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Key Findings
  • 1.2. Methodology

2.0. INTRODUCTION

  • 2.1. Reason for the Report
    • 2.1.1. Why Investing Is Important
    • 2.1.2. Beyond the Seed Stage
    • 2.1.3. Identify Value Drivers

3.0. TRENDS AND EXPECTATIONS

  • 3.1. Corporate Venture Capital Spurs M&A Activity
  • 3.2. Licensing Deals to Grow
  • 3.3. Venture Capital's Strong Outlook
  • 3.4. Therapeutic Areas of Focus
    • 3.4.1. The Outcomes Push
  • 3.5. In Need of New Strategies
    • 3.5.1. Modeling Potential Success
    • 3.5.2. Crowdfunding
      • 3.5.2.1. A Lifeline

4.0. GROWTH THROUGH SOPHISTICATED COLLABORATIONS

  • 4.1. Determining Product Value
    • 4.1.1. Quantifiable Issues
    • 4.1.2. Revolutionary Value
    • 4.1.3. Global Value
  • 4.2. Changing Roles and Market Landscapes

5.0. VENTURE CAPITAL VS. CORPORATE CAPITAL

  • 5.1. New Fundraising Vistas
  • 5.2. Venture Arms with a Strategy
  • 5.3. Corporate Capital Fundamentals

6.0. INVESTMENT DOLLAR TRENDS

  • 6.1. Annual Numbers
    • 6.1.1. Trends in 2013
    • 6.1.2. Trends in 2012
    • 6.1.3. Trends in 2011
    • 6.1.4. Trends in 2010
    • 6.1.5. Trends in 2009
  • 6.2. Personalized Medicine

7.0. KEY DEALS

  • 7.1. Ablynx NV
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.2. Acetylon Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.3. AC Immune SA
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.4. Adimab
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.5. Aileron Therapeutics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.6. Algeta ASA
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.7. Alios BioPharma Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.8. Alkermes
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.9. Alnylam Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.10. Amylin Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.11. Ardea Biosciences
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.12. Atara Biotherapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.13. Avila Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.14. Boston Biomedical
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.15. Cellectis
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.16. Clarus Ventures
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.17. CoStim Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.18. Covagen AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.19. Dicerna Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.20. Editas Medicine
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.21. Enanta Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.22. Endocyte Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.23. Evotec AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.24. Forma Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.25. Galapagos NV
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.26. Gemin X Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.27. Genmab
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.28. GlaxoSmithKline
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.29. Human Genome Sciences
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.30. immatics Biotechnologies GmbH
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.31. Inhibitex
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.32. Inhibrx
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.33. Isis Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.34. Juno Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.35. Macrogenics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.36. Mannkind Corp.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.37. Medigene AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.38. Melinta Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.39. Merck
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.40. Mesoblast Ltd.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.41. Micromet AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.42. Moderna Therapeutics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.43. OncoMed Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.44. Onyx Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.45. Otonomy Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.46. Pharmasset
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.47. Plexxikon Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.48. Reata Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.49. Royalty Pharma
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.50. Seattle Genetics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.51. Sutro Biopharma Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.52. Thesan Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.53. UCB Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.54. Voyager Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.55. Xenon Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.56. Xoma Corp.
    • Description of Deal
    • Size
    • Agreement Type
    • Details

LIST OF EXHIBITS

1.0 EXECUTIVE SUMMARY

  • Summary Exhibit: Biotechnology Investment Dollars, 2012 and 2013 ($ millions)

6.0 INVESTMENT DOLLAR TRENDS

  • Exhibit 1: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
  • Exhibit 2: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
  • Exhibit 3: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
  • Exhibit 4: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
  • Exhibit 5: Breakdown of Overall and Biotech Venture Capital Dollars, Billions of Dollars US Invested in 2013
  • Exhibit 6: Venture Capital Dollar Trends, Biotechnology Dollars Invested by Quarter, 2009-2013
  • Exhibit 7: Health Care as a Percentage of Total Venture Investment, 2009-2012
  • Exhibit 8: Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
  • Exhibit 9: Number of Biotech Series A Companies by Indication, 2009, Raising More than $2 Million
  • Exhibit 10: Number of Biotech Series A Companies by Indication, 2010, Raising More Than $2 Million
  • Exhibit 11: Number of Biotech Series A Companies by Indication, 2011, Raising More Than $2 Million
  • Exhibit 12: Number of Biotech Series A Companies by Indication, 2012, Raising More Than $2 Million
  • Exhibit 13: Biotech Total Deal Value, 2005-2012, Minimum Two Big Exits
  • Exhibit 14: Personalized Medicine M&A with Disclosed Values, 2010-2013
  • Exhibit 15: Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013
  • Exhibit 16: Personalized Medicine Disclosed M&A Deal Value by Focus, 2010-2013
  • Exhibit 17: Personalized Medicine Financings, 2010-2013
  • Exhibit 18: Personalized Medicine Financings by Type, Number of Deals, 2010-2013
  • Exhibit 19: Personalized Medicine Financings by Category, Number of Deals, 2010-2013
Back to Top